Inflammatory Bowel Disease (IBD) and Covid-19 Infection (MICI-Covid-19)

University Hospital, Strasbourg, France

Status: Unknown

Conditions: Inflammatory Bowel Disease

Study type: Observational

Funder types: Other

Identifiers

NCT04492267

7930

Details and patient eligibility

About

Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.

Enrollment: 700 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over the age of 18 years
• IBD patients (Crohn's disease, ulcerative colitis, indeterminate colitis)
• Patient agreeing to participate in the study

Exclusion criteria

• Patient unable to understand the study protocol or to answer simple anamnestic questions due to language barrier
• Patient under guardianship or trusteeship
• Patient under safeguard of justice